309 related articles for article (PubMed ID: 31758502)
1. Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients.
Pang Y; Khatri A; Suleiman AA; Othman AA
Clin Pharmacokinet; 2020 Mar; 59(3):311-326. PubMed ID: 31758502
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I-III Clinical Trials.
Suleiman AA; Minocha M; Khatri A; Pang Y; Othman AA
Clin Pharmacokinet; 2019 Oct; 58(10):1309-1321. PubMed ID: 31054118
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials.
Suleiman AA; Khatri A; Minocha M; Othman AA
Clin Pharmacokinet; 2019 Mar; 58(3):375-387. PubMed ID: 30123942
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis.
Khatri A; Eckert D; Oberoi R; Suleiman A; Pang Y; Cheng L; Othman AA
J Clin Pharmacol; 2019 Dec; 59(12):1656-1668. PubMed ID: 31257614
[TBL] [Abstract][Full Text] [Related]
5. Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis.
Khatri A; Cheng L; Camez A; Ignatenko S; Pang Y; Othman AA
Clin Pharmacokinet; 2019 Jun; 58(6):805-814. PubMed ID: 30574672
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
[TBL] [Abstract][Full Text] [Related]
7. Exposure-Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients.
Khatri A; Suleiman AA; Polepally AR; Othman AA
Clin Pharmacol Ther; 2020 Feb; 107(2):378-387. PubMed ID: 31355921
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial.
Ohtsuki M; Fujita H; Watanabe M; Suzaki K; Flack M; Huang X; Kitamura S; Valdes J; Igarashi A
J Dermatol; 2019 Aug; 46(8):686-694. PubMed ID: 31237727
[TBL] [Abstract][Full Text] [Related]
9. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
Reich K; Gooderham M; Thaçi D; Crowley JJ; Ryan C; Krueger JG; Tsai TF; Flack M; Gu Y; Williams DA; Thompson EHZ; Paul C
Lancet; 2019 Aug; 394(10198):576-586. PubMed ID: 31280967
[TBL] [Abstract][Full Text] [Related]
10. Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis.
Jauslin P; Kulkarni P; Li H; Vatakuti S; Hussain A; Wenning L; Kerbusch T
Clin Pharmacokinet; 2019 Aug; 58(8):1059-1068. PubMed ID: 30915660
[TBL] [Abstract][Full Text] [Related]
11. Exposure-Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis.
Suleiman AA; Khatri A; Oberoi RK; Othman AA
Clin Pharmacokinet; 2020 May; 59(5):575-589. PubMed ID: 31667790
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of risankizumab in Japanese patients with generalized pustular psoriasis or erythrodermic psoriasis: Primary analysis and 180-week follow-up results from the phase 3, multicenter IMMspire study.
Yamanaka K; Okubo Y; Yasuda I; Saito N; Messina I; Morita A
J Dermatol; 2023 Feb; 50(2):195-202. PubMed ID: 36514850
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis.
Timmermann S; Hall A
Basic Clin Pharmacol Toxicol; 2019 Jul; 125(1):16-25. PubMed ID: 30661290
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
Blauvelt A; Leonardi CL; Gooderham M; Papp KA; Philipp S; Wu JJ; Igarashi A; Flack M; Geng Z; Wu T; Camez A; Williams D; Langley RG
JAMA Dermatol; 2020 Jun; 156(6):649-658. PubMed ID: 32267471
[TBL] [Abstract][Full Text] [Related]
15. Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis.
Khalilieh S; Hussain A; Montgomery D; Levine V; Shaw PM; Bodrug I; Mekokishvili L; Bailey-Smith C; Glasgow XS; Cheng A; Martinho M; Iwamoto M
Br J Clin Pharmacol; 2018 Oct; 84(10):2292-2302. PubMed ID: 29926968
[TBL] [Abstract][Full Text] [Related]
16. Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis.
Li W; Ghamrawi R; Haidari W; Feldman SR
Ann Pharmacother; 2020 Apr; 54(4):380-387. PubMed ID: 31672037
[No Abstract] [Full Text] [Related]
17. Risankizumab: A Review in Moderate to Severe Plaque Psoriasis.
Blair HA
Drugs; 2020 Aug; 80(12):1235-1245. PubMed ID: 32632826
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics and Exposure-Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis.
Thakre N; D'Cunha R; Goebel A; Liu W; Pang Y; Suleiman AA
Rheumatol Ther; 2022 Dec; 9(6):1587-1603. PubMed ID: 36178584
[TBL] [Abstract][Full Text] [Related]
19. Update on risankizumab for the treatment of moderate to severe psoriasis.
Al-Janabi A; Warren RB
Expert Opin Biol Ther; 2020 Nov; 20(11):1245-1251. PubMed ID: 32933320
[TBL] [Abstract][Full Text] [Related]
20. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
Papp KA; Blauvelt A; Bukhalo M; Gooderham M; Krueger JG; Lacour JP; Menter A; Philipp S; Sofen H; Tyring S; Berner BR; Visvanathan S; Pamulapati C; Bennett N; Flack M; Scholl P; Padula SJ
N Engl J Med; 2017 Apr; 376(16):1551-1560. PubMed ID: 28423301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]